Folic acid reduces risk of neural tube defects linked to HIV drug dolutegravir

Dolutegravir is a preferred medication for treating HIV infection, but it recently has been linked to a 6- to 9-fold increase in the risk for neural tube defects among babies born to mothers receiving the drug during early gestation. Researchers at Baylor College of Medicine suspected that folic acid (vitamin B9), which is known to prevent the vast majority of neural tube defect cases, could be a part of the puzzle of dolutegravir's negative side effects.

source https://www.lifetechnology.com/blogs/life-technology-news-blog/folic-acid-reduces-risk-of-neural-tube-defects-linked-to-hiv-drug-dolutegravir